2021
Triple-negative breast cancer: promising prognostic biomarkers currently in development
Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Review Of Anticancer Therapy 2021, 21: 135-148. PMID: 33198517, PMCID: PMC8174647, DOI: 10.1080/14737140.2021.1840984.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerHuman epidermal growth factor receptor 2Vascular endothelial growth factorHomologous recombination deficiencyBreast cancerEpidermal growth factor receptorGrowth factor receptorPredictive biomarkersTreatment optionsFibroblast growth factor receptorManagement of TNBCEpidermal growth factor receptor 2Factor receptorGrowth factor receptor 2PI3K/Akt/mTORLimited treatment optionsNTRK gene fusionsFactor receptor 2Akt/mTOREndothelial growth factorCell-free DNAAntibody-drug conjugatesClinical outcomesImmune biomarkersPoor prognosis
2018
Implementing Liquid Biopsies in Clinical Trials
Lustberg M, Stover D, Chalmers J. Implementing Liquid Biopsies in Clinical Trials. The Cancer Journal 2018, 24: 61-64. PMID: 29601331, PMCID: PMC5880324, DOI: 10.1097/ppo.0000000000000309.Peer-Reviewed Original ResearchConceptsClinical trialsLiquid biopsyReal-time biopsySurrogate efficacy endpointsTreatment response evaluationMultiple clinical trialsRoutine clinical practiceCell-free DNATumor-specific biomarkersEfficacy endpointBlood markersPredictive biomarkersPharmacodynamic biomarkersPrognostic biomarkerTreatment selectionTumor markersBiopsyClinical practiceDisease statusTumor cellsResponse evaluationAdditional studiesBiomarkersTrialsExtracellular vesicles